![[noalt]](https://www-bg2d96gu-staging.s3.amazonaws.com/media/images/news1.max-200x200.png)
Read the latest news from OneOme
OneOme Introduces RightMed Oncology: Empowering Clinicians to Personalize Treatment and Reduce Toxicity Risk with Pharmacogenomics
MINNEAPOLIS, MN - April 2, 2024
OneOme announces its new approach to improving medication safety for cancer patients through focused germline pharmacogenomics (PGx) testing. RightMed Oncology is uniquely designed to help oncologists elevate their standard of care – to decrease the risk of chemotherapy-induced toxicity and improve medication safety and efficacy for supportive care medications for mental health, pain management, and chemotherapy-induced nausea and vomiting.
OneOme provides RightMed® test to Ochsner Health, advancing personalized precision medicine for employees.
Minneapolis | Ochsner Health, one of the leading nonprofit, multi-specialty health care systems in the Gulf South, has contracted with OneOme® to provide pharmacogenomic (PGx) testing for their patients and covered employees and family members through OneOme’s RightMed® solution.
Entira Family Clinics provides patients the RightMed® PGx test offered by OneOme®.
Minneapolis | Entira Family Clinics now provides interested patients with the opportunity to undergo the RightMed® PGx test offered by OneOme®.
Alliance Healthcare Netherlands and OneOme bring personalized medication closer.
Veghel / Minneapolis | Alliance Healthcare Netherlands has extended its contract with OneOme for the RightMed® pharmacogenomic test by three years. The test is available at more than 100 Alphega and Boots pharmacies, online at https://www.bootsapotheek.nl/ and at selected pharmacy locations in the Netherlands.
Read more >
OneOme Medical Affairs Team Presents Panel Discussion at PMLS
OneOme’s VP of Medical Affairs & Senior Medical Director, Julie England, MD, alongside Medical Affairs team members Ghada Elnashar, PharmD, MS, and Victor Tam, PharmD, shared the stage for a panel discussion with Dr. Scott Betzelos (Blue Care Network) and Michael Schuh, PharmD (Mayo) on the successful implentation of a PGx program at PMLS in Florida this week.
A Response to Clinical use of pre-emptive pharmacogenetic programmes in The Lancet
From James Kelley, MD, PhD, Chief Medical Officer at OneOme - I have an autoimmune condition and am currently taking seven prescription drugs. Over the years, I have suffered adverse drug reactions that have caused me more than just nausea, rashes, hospitalizations; there’s an emotional toll. I’ve been excited about how a medication will help me only to end up worse off. ADRs not only worsen clinical outcomes - they discourage patients who just want to feel better.
Hennepin Healthcare contracts with OneOme® to offer RightMed® PGx (Pharmacogenomic) test as part of personalized medication program
Minneapolis, MN | OneOme, a leading pharmacogenomic and precision medicine company, has signed a contract with Hennepin Healthcare to provide pharmacogenomic (PGx) testing to patients. PGx testing and results helps prevent adverse drug events and improve patient outcomes with the use of medications best suited to a patient’s genetic makeup and has a high applicability to pain management, cardiology, oncology, and mental/behavioral health.
Read more >
Jason Walker, PhD, named Lab Director at OneOme.
Minneapolis based pharmacogenomics precision medicine company, OneOme, announces James Kelley, MD, PhD as Chief Medical Officer.
OneOme Supports Bipartisan Led “Right Drug Dose Now” Act – Should Help Implement Better Precision Medicine and Prevention of Adverse Drug Events
OneOme, a leading pharmacogenomic and precision medicine company was a named supporter of the “Right Drug Dose Now” Act, which was introduced at the end of February, 2022. A bipartisan act, brought by Representatives Tom Emmer (MN-06) and Eric Swalwell (CA-15), the “Right Drug Dose Now” Act looks to better enable pharmacogenetic testing to prevent adverse drug events and encourage the use of therapies tailored to a patient’s genetic makeup.
Blue Care Network (BCN), Blue Cross Blue Shield of Michigan's HMO Business Unit to Advance Precision Medicine by Using OneOme's RightMed® for Populations Program for the Blue Cross Personalized Medicine℠ Program
"We’re very excited about this new partnership with one of the more innovative and forward-thinking Health Plans in the country. We’re very confident that OneOme will help BCN achieve their precision medicine program goals and reduce total cost of care and improve patient health outcomes by reducing adverse drug reactions." said Pat McIntyre, CEO of OneOme.
Tabula Rasa HealthCare and OneOme Combine Powerful Precision Medication Tools to Improve Medication Safety, Efficacy, and Adherence
MOORESTOWN, N.J., April 15, 2021 /PRNewswire/ -- Tabula Rasa HealthCare, Inc® (TRHC) (NASDAQ: TRHC), a leading healthcare technology company advancing the safe use of medications, today announced it has partnered with OneOme, co-founded by Mayo Clinic, a provider of solutions for implementing pharmacogenomics (PGx) in patient care to advance more optimal patient outcomes.
Walgreens Boots Alliance subsidiary Alliance Healthcare launches pharmacogenomics as an employee benefit, powered by OneOme
The RightMed Test offers Alliance Healthcare employees a path to more personalized prescriptions.
Minneapolis, MN and 's-Hertogenbosch, Netherlands (November 13 2020) – OneOme, LLC today announced a new agreement with Alliance Healthcare Netherlands (a subsidiary of Walgreens Boots Alliance) to provide pharmacogenomic testing via the RightMed Test to Alliance Healthcare employees and immediate family members.
OneOme comments on FDA’s Table of Pharmacogenetic Associations
On February 20, FDA released a Table of Pharmacogenetic Associations (updated February 25) and opened a docket for gathering feedback and comments.
As a leader in the pharmacogenetics (PGx) space, OneOme believes this is a positive step toward achieving consensus evidentiary standards for PGx testing. Our intent in providing the following comments was to help move toward this consensus by offering constructive feedback using our team’s extensive experience in evaluation of PGx evidence and our practical knowledge of how clinicians use PGx testing in patient care.*
Family Care Path Partners With OneOme To Add Pharmacogenomic Testing To Its Genetic Wellness Program
CLEVELAND and MINNEAPOLIS, Dec. 2, 2019 /PRNewswire/ -- Family Care Path, Inc. a health technology company that brings applications benefiting people to the healthcare market, today announced a new partnership with Minneapolis-based pharmacogenomic (PGx) solutions company, OneOme, LLC. Through this partnership, Family Care Path will be offering OneOme's RightMed® Test to its customers along with its MyLegacy application, a family history-based genetic risk assessment.
OneOme And Walgreens Boots Alliance Subsidiary Alliance Healthcare Partner To Bring Personalized Prescriptions To The Netherlands
MINNEAPOLIS and 'S-HERTOGENBOSCH, Netherlands, Nov. 19, 2019 /PRNewswire/ -- OneOme today announced a pilot partnership with Alliance Healthcare Netherlands (a wholly owned subsidiary of Walgreens Boots Alliance) that will bring pharmacogenomic testing to selected Boots and Alphega Pharmacy locations throughout the Netherlands.
OneOme Appoints Healthcare Veteran Patrick McIntyre as CEO
McIntyre Brings 30+ Years Of Experience As A Healthcare Executive, Including COO And CFO Positions
MINNEAPOLIS – July 8, 2019 – OneOme has named Patrick McIntyre, a healthcare executive with more than three decades of experience in management, operations, and finance, as its Chief Executive Officer. McIntyre replaces Paul Owen, who joined to lead the company in 2015 and who will oversee the transition.
OneOme named “Best Overall Genomics Company” in 2019 MedTech Breakthrough Awards
June 20, 2019 - Minneapolis, MN - OneOme, a leading provider of pharmacogenomics solutions, today announced it won a MedTech Breakthrough Award in the category of Best Overall Genomics Company.